SEC Company Response from Outlook Therapeutics, (OTLK) — May 4, 2016
Outlook Therapeutics, Inc.
Date: May 4, 2016 · CIK: 0001649989 · Accession: 0001571049-16-014798
AI Filing Summary & Sentiment
File numbers found in text: 333-209011
Letter
Re: Oncobiologics, Inc.
May 4, 2016
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Suzanne Hayes
Registration Statement on Form S-1
File No. 333-209011
Acceleration Request
Requested Date: May 5, 2016
Requested Time: 4:00 p.m., Eastern Time
Ladies and gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Jefferies LLC and Barclays Capital Inc., as representatives of the several underwriters, hereby join Oncobiologics, Inc. in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-209011) to become effective on Thursday, May 5, 2016, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter.
Additionally, pursuant to Rule 460 of the Act, we hereby advise you that the Preliminary Prospectus dated April 27, 2016, was distributed by us, as representatives of the several underwriters, approximately as follows from April 27, 2016 through the date hereof:
Copies to underwriters
Copies to dealers
Copies to institutional investors
Copies to others/retail
Total 1,254
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
Very truly yours,
JEFFERIES LLC
Show Raw Text
CORRESP
1
filename1.htm
May 4, 2016
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Suzanne Hayes
Re:
Oncobiologics, Inc.
Registration Statement on Form S-1
File No. 333-209011
Acceleration Request
Requested Date:
May 5, 2016
Requested Time:
4:00 p.m., Eastern Time
Ladies and gentlemen:
In accordance with
Rule 461 under the Securities Act of 1933, as amended (the “Act”), Jefferies LLC and Barclays Capital
Inc., as representatives of the several underwriters, hereby join Oncobiologics, Inc. in requesting that the Securities and Exchange
Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1
(File No. 333-209011) to become effective on Thursday, May 5, 2016, at 4:00 p.m., Eastern Time, or as soon as practicable thereafter.
Additionally, pursuant
to Rule 460 of the Act, we hereby advise you that the Preliminary Prospectus dated April 27, 2016, was distributed by us, as representatives
of the several underwriters, approximately as follows from April 27, 2016 through the date hereof:
Copies to underwriters
661
Copies to dealers
0
Copies to institutional investors
588
Copies to others/retail
5
Total
1,254
We have been informed
by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act
of 1934, as amended, to the extent applicable.
Very truly yours,
JEFFERIES LLC
BARCLAYS CAPITAL INC.,
As Representatives
[Signature Page Follows]
JEFFERIES LLC
By:
/s/ Matthew Kim
Name: Matthew Kim
Title: Managing Director
BARCLAYS CAPITAL INC.
By:
/s/ Victoria Hale
Name: Victoria Hale
Title: Vice President
cc:
Pankaj Mohan, Ph.D., Oncobiologics, Inc.
Lawrence A. Kenyon, Oncobiologics, Inc.
Stuart M. Cable, Goodwin Procter LLP
Edwin O’Connor, Goodwin Procter LLP
Seo Salimi, Goodwin Procter LLP
Yvan-Claude Pierre, Cooley LLP
Daniel I. Goldberg, Cooley LLP
Marianne Sarrazin, Cooley LLP
[signature page to acceleration request
letter]